Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand

Lerdkiattikorn, P.; Chaikledkaew, Usa; Lausoontornsiri, Wirote; Chindavijak, Somjin; Khuhaprema, T.; Tantai, Narisa; Teerawattananon, Yot

doi:10.1586/14737167.2015.972379

Cited by 9 publications

(24 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the remaining study, the cost of capecitabine acquisition was reported as almost 10 times the cost of 5-FU, which is substantially higher than reported in other studies. 32 Notably, there was no full evaluation comparing capecitabine to 5FU in stage II CRC.…”

Section: Ac Vs No Acmentioning

confidence: 99%

“…15 Amongst stage III studies, 7 of 8 (88%) full economic evaluations determined that FOLFOX was cost-effective compared to 5-FU alone. 22,26,30,32,34,[39][40][41][42][43] The remaining study modelled strategies that included different treatments for metastatic recurrence, limiting the assessment of AC alone. 32 Additionally, Pandor et al concluded that FOLFOX dominates capecitabine in stage III.…”

Section: Oxaliplatin-based Acmentioning

confidence: 99%

“…22,26,30,32,34,[39][40][41][42][43] The remaining study modelled strategies that included different treatments for metastatic recurrence, limiting the assessment of AC alone. 32 Additionally, Pandor et al concluded that FOLFOX dominates capecitabine in stage III. 39 Conversely, Soni et al concluded that 5-FU dominates CAPOX but as previously noted, capecitabine-treated patients in this study were less likely to receive the full intensity of treatment, limiting e cacy.…”

Section: Oxaliplatin-based Acmentioning

confidence: 99%

See 2 more Smart Citations

Health economic evidence for adjuvant chemotherapy in stage II and III colorectal cancer: a systematic review

Gibbs

Tie

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective: The aims of this study was to appraise the health economic evidence for adjuvant chemotherapy (AC) strategies in stage II and III colorectal cancer (CRC) and to identify gaps in the available evidence that might inform further research.Method : A systematic review of published economic evaluations was undertaken. Four databases were searched and full-text publications in English were screened for inclusion. A narrative synthesis was performed to summarise the evidence.Results: Thirty-eight studies were identified and stratified by cancer stage and AC strategy. The majority (89%) were full economic evaluations considering both health outcomes, usually measured as quality-adjusted life years (QALYs), and costs. AC was found to be cost-effective compared to no AC for both stage II and III CRC. Oral and oxaliplatin-based AC was cost-effective for stage III. Three months of CAPOX was cost-effective compared to 6-month in high-risk stage II and stage III CRC. Preliminary evidence suggests that biomarker approaches to AC selection in stage II can reduce costs and improve health outcomes. Notably, assessment of QALYs were predominantly reliant on a small number of non-contemporary health-utility studies. Only 32% of studies considered societal costs such as travel and time off work. Conclusions: Published economic evaluations consistently supported the use of AC in stage II and III colorectal cancer. Biomarker-driven approaches to patient selection have great potential to be cost-effective, but more robust clinical and economic evidence is warranted. Patient surveys embedded into clinical trials may address critical knowledge gaps regarding accurate assessment of QALYs and societal costs in the modern era.

show abstract

Section: Ac Vs No Acmentioning

confidence: 99%

Section: Oxaliplatin-based Acmentioning

confidence: 99%

Section: Oxaliplatin-based Acmentioning

confidence: 99%

See 1 more Smart Citation

Health economic evidence for adjuvant chemotherapy in stage II and III colorectal cancer: a systematic review

Gibbs

Tie

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…prolong survival of the patients; nevertheless, the mortality and morbidity of the disease are high. Moreover, colonic cancer treatment costs become higher than in the past due to development of new-targeted therapies (Faivre, 1994;Lerdkiattikorn et al, 2015). Prevention can be one of the most cost-effective measures for low resources countries such as Thailand (Khuhaprema and Srivatanakul, 2008;Lepage et al, 2010).…”

Section: Modifiable Factors and Colon Cancer Risk In Thai Populationmentioning

confidence: 99%

Modifiable Factors and Colon Cancer Risk in Thai Population

Chottanapund

Chamroonsawasdi

Tunyasitthisundhorn

et al. 2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

To demonstrate the possible impact of modifiable factors on colon cancer development in Thai population, we conducted this case-control study from June 2016 until June 2017. The study was conducted in 11 Thai provincial hospitals. The hospitals in this study were selected by stratification by regions. Patients included 504 ones who were newly diagnosed with colon cancer within 1 month. In the control group, 997 health individuals were enrolled. Both case and control were adjusted by age. The results of this study showed that age and socioeconomic factors were associated with colon cancer risk. In addition, it was found that family history of colon cancer had very high association with colon cancer risk. Behavioral factors, including smoking, inadequate physical exercise, and salty food consumption were associated with colon cancer. We detected no association between obesity, alcohol consumption, and colon cancer. The results suggested that colon cancer might have higher association with genetic factors than behavioral factors among Thai patients. Based on the results of this study, stop smoking and promote adequate physical activity are suggested to reduce the incidence of colon cancrr among Thai patients.

show abstract

“…Moreover, decision makers' work nowadays is likely to be more difficult than it was 50 years ago, when only one or a few treatment choices were available for each disease and at relatively low cost. For example, only one option was available for adjuvant therapy for stage III colon cancer in 1989 [2], but there are now nine choices in the recent evaluation, of which the most expensive treatment regimen has a medicine price that is 32 times higher than the least expensive alternative [3].…”

mentioning

confidence: 99%

Health Technology Assessment as a Priority-Setting Tool for Universal Health Coverage: The Call for Global Action at the Prince Mahidol Award Conference 2016

Teerawattananon

Luz

2015

PharmacoEconomics

Self Cite

View full text Add to dashboard Cite

Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand

Abstract: The adjuvant FOLFOX and FOLFIRI as the first-line treatment for metastatic disease would be cost-effective with an incremental cost-effectiveness ratio of 299,365 Thai baht per QALY gained based on a societal perspective if both prices of FOLFOX and FOLFIRI were decreased by 40%.

Cited by 9 publications

References 32 publications

Health economic evidence for adjuvant chemotherapy in stage II and III colorectal cancer: a systematic review

Health economic evidence for adjuvant chemotherapy in stage II and III colorectal cancer: a systematic review

Modifiable Factors and Colon Cancer Risk in Thai Population

Health Technology Assessment as a Priority-Setting Tool for Universal Health Coverage: The Call for Global Action at the Prince Mahidol Award Conference 2016

Contact Info

Product

Resources

About